The cost of cancer drugs became a major talking point at this year’s ASCO conference, where doctors raised concerns about the “financial toxicity” patients face in paying for very expensive
While ASCO often showcases the benefits of new cancer therapies, it was a well-established drug that proved to be a talking point at this year’s conference in Chicago.
A combination of Novartis’ 'next generation' CAR-T drug CTL119 with Janssen and AbbVie's Imbruvica has cleared all signs of chronic lymphocytic leukaemia from eight out of nine patients in
Novartis has struck another deal to build its position in radiopharmaceuticals, agreeing to pay $1 billion upfront for radioligand therapy (RLT) developer Mariana Oncology
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.